Everything on Pharma Sector

The valuation gap between Eli Lilly (74x P/E) and Novo Nordisk (14x P/E) is extreme, with Novo’s price implying minimal future growth. This divergence creates a contrarian opportunity for Novo.

Impact: Re-rating of Novo Nordisk could provide significant upside, while Lilly’s high valuation leaves little room for error in future earnings reports.

— from Geopolitical Shocks and AI Disruption in Markets · Aktien fürs Leben· Mar 04, 2026